Establishment of C20Mab‑11, a novel anti‑CD20 monoclonal antibody, for the detection of B cells

Furusawa,Yoshikazu; Kaneko,Mika Kato; Kato,Yukinari

doi:10.3892/ol.2020.11753

Establishment of C20Mab‑11, a novel anti‑CD20 monoclonal antibody, for the detection of B cells

Authors:
- Yoshikazu Furusawa
- Mika Kato Kaneko
- Yukinari Kato
View Affiliations

Affiliations: Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980‑8575, Japan
Published online on: June 17, 2020 https://doi.org/10.3892/ol.2020.11753
Pages: 1961-1967
Copyright : © Furusawa et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

CD20 is one of several B‑lymphocyte antigens that has been shown to be an effective target for the detection and treatment of B‑cell lymphomas. Sensitive and specific monoclonal antibodies (mAbs) are required for every application used for the diagnosis of B‑cell lymphoma. Although many anti‑CD20 mAbs have been established, the types of applications, those anti‑CD20 can be used in, are limited. In this study, we aimed to establish novel anti‑CD20 mAbs to be used for broad applications, such as flow cytometry, western blot, and immunohistochemical analyses, using the Cell‑Based Immunization and Screening (CBIS) method. One of the established mAbs, C20Mab‑11 (IgM, kappa), detected overexpression of CD20 in CHO‑K1 or LN229 cell lines, indicating that C20Mab‑11 is specific for CD20. In western blot analyses, C20Mab‑11 detected not only overexpression of CD20 in CHO‑K1 or LN229 cell lines, but also CD20 of BALL‑1 and Raji cells with both sensitivity and specificity. Furthermore, C20Mab‑11 strongly stained B cells of the lymph follicle and B cell lymphomas in immunohistochemical analyses. These results indicate that C20Mab‑11 develped by CBIS method, is useful for the detection of CD20 in lymphoma tissues by flow cytometry, western blot, and immunohistochemical analyses and potentially could be beneficial for the treatment of B cell lymphomas.

View Figures

View References

1	Polyak MJ, Li H, Shariat N and Deans JP: CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins. J Biol Chem. 283:18545–18552. 2008. View Article : Google Scholar : PubMed/NCBI
2	Li H, Ayer LM, Lytton J and Deans JP: Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem. 278:42427–42434. 2003. View Article : Google Scholar : PubMed/NCBI
3	Tedder TF, Boyd AW, Freedman AS, Nadler LM and Schlossman SF: The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol. 135:973–979. 1985.PubMed/NCBI
4	Rawstron AC, Owen RG, Davies FE, Johnson RJ, Jones RA, Richards SJ, Evans PA, Child JA, Smith GM, Jack AS and Morgan GJ: Circulating plasma cells in multiple myeloma: Characterization and correlation with disease stage. Br J Haematol. 97:46–55. 1997. View Article : Google Scholar : PubMed/NCBI
5	Chu PG, Loera S, Huang Q and Weiss LM: Lineage determination of CD20- B-Cell neoplasms: An immunohistochemical study. Am J Clin Pathol. 126:534–544. 2006. View Article : Google Scholar : PubMed/NCBI
6	Kato Y and Kaneko MK: A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci Rep. 4:59242014. View Article : Google Scholar : PubMed/NCBI
7	Itai S, Fujii Y, Nakamura T, Chang YW, Yanaka M, Saidoh N, Handa S, Suzuki H, Harada H, Yamada S, et al: Establishment of CMab-43, a sensitive and specific Anti-CD133 monoclonal antibody, for immunohistochemistry. Monoclon Antib Immunodiagn Immunother. 36:231–235. 2017. View Article : Google Scholar : PubMed/NCBI
8	Yamada S, Itai S, Nakamura T, Yanaka M, Kaneko MK and Kato Y: Detection of high CD44 expression in oral cancers using the novel monoclonal antibody, C44Mab-5. Biochem Biophys Rep. 14:64–68. 2018.PubMed/NCBI
9	Yamada S, Itai S, Nakamura T, Yanaka M, Chang YW, Suzuki H, Kaneko MK and Kato Y: Monoclonal antibody L1Mab-13 detected human PD-L1 in lung cancers. Monoclon Antib Immunodiagn Immunother. 37:110–115. 2018. View Article : Google Scholar : PubMed/NCBI
10	Furusawa Y, Yamada S, Itai S, Sano M, Nakamura T, Yanaka M, Fukui M, Harada H, Mizuno T, Sakai Y, et al: PMab-210: A monoclonal antibody against pig podoplanin. Monoclon Antib Immunodiagn Immunother. 38:30–36. 2019. View Article : Google Scholar : PubMed/NCBI
11	Furusawa Y, Kaneko MK, Nakamura T, Itai S, Fukui M, Harada H, Yamada S and Kato Y: Establishment of a monoclonal antibody PMab-231 for tiger podoplanin. Monoclon Antib Immunodiagn Immunother. 38:89–95. 2019. View Article : Google Scholar : PubMed/NCBI
12	Furusawa Y, Takei J, Sayama Y, Yamada S, Kaneko MK and Kato Y: Development of an anti-bear podoplanin monoclonal antibody PMab-247 for immunohistochemical analysis. Biochem Biophys Rep. 18:1006442019.PubMed/NCBI
13	Furusawa Y, Yamada S, Itai S, Nakamura T, Takei J, Sano M, Harada H, Fukui M, Kaneko MK and Kato Y: Establishment of a monoclonal antibody PMab-233 for immunohistochemical analysis against Tasmanian devil podoplanin. Biochem Biophys Rep. 18:1006312019.PubMed/NCBI
14	Furusawa Y, Yamada S, Itai S, Nakamura T, Yanaka M, Sano M, Harada H, Fukui M, Kaneko MK and Kato Y: PMab-219: A monoclonal antibody for the immunohistochemical analysis of horse podoplanin. Biochem Biophys Rep. 18:1006162019.PubMed/NCBI
15	Kato Y, Furusawa Y, Itai S, Takei J, Nakamura T, Sano M, Harada H, Yamada S and Kaneko MK: Establishment of an anticetacean podoplanin monoclonal antibody PMab-237 for immunohistochemical analysis. Monoclon Antib Immunodiagn Immunother. 38:108–113. 2019. View Article : Google Scholar : PubMed/NCBI
16	Kato Y, Furusawa Y, Yamada S, Itai S, Takei J, Sano M and Kaneko MK: Establishment of a monoclonal antibody PMab-225 against alpaca podoplanin for immunohistochemical analyses. Biochem Biophys Rep. 18:1006332019.PubMed/NCBI
17	Kato Y, Yamada S, Furusawa Y, Itai S, Nakamura T, Yanaka M, Sano M, Harada H, Fukui M and Kaneko MK: PMab-213: A monoclonal antibody for immunohistochemical analysis against pig podoplanin. Monoclon Antib Immunodiagn Immunother. 38:18–24. 2019. View Article : Google Scholar : PubMed/NCBI
18	Tedder TF, McIntyre G and Schlossman SF: Heterogeneity in the B1 (CD20) cell surface molecule expressed by human B-lymphocytes. Mol Immunol. 25:1321–1330. 1988. View Article : Google Scholar : PubMed/NCBI
19	Wang Y, Xu H, Liu T, Huang M, Butter PP, Li C, Zhang L, Kao GD, Gong Y, Maity A, et al: Temporal DNA-PK activation drives genomic instability and therapy resistance in glioma stem cells. JCI Insight. 3:980962018. View Article : Google Scholar : PubMed/NCBI
20	Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N and Anderson DR: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 83:435–445. 1994. View Article : Google Scholar : PubMed/NCBI
21	Keating GM: Rituximab: A review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs. 70:1445–1476. 2010. View Article : Google Scholar : PubMed/NCBI
22	Itai S, Ohishi T, Kaneko MK, Yamada S, Abe S, Nakamura T, Yanaka M, Chang YW, Ohba SI, Nishioka Y, et al: Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma. Oncotarget. 9:22480–22497. 2018. View Article : Google Scholar : PubMed/NCBI
23	Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, et al: Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood. 96:1259–1266. 2000. View Article : Google Scholar : PubMed/NCBI
24	Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, Schilder RJ, Wiseman G and White CA: Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study. Blood. 103:4429–4431. 2004. View Article : Google Scholar : PubMed/NCBI
25	Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MH, Wooldridge J, Kloczko J, Holowiecki J, Hellmann A, et al: Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: A phase 1–2 study. Blood. 111:1094–1100. 2008. View Article : Google Scholar : PubMed/NCBI
26	Mossner E, Brunker P, Moser S, Püntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, et al: Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 115:4393–4402. 2010. View Article : Google Scholar : PubMed/NCBI
27	Link BK and Friedberg JW: Monoclonal antibodies in lymphoma: The first decade. Semin Hematol. 45:71–74. 2008. View Article : Google Scholar : PubMed/NCBI
28	Kennedy GA, Tey SK, Cobcroft R, Marlton P, Cull G, Grimmett K, Thomson D and Gill D: Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: A retrospective review. Br J Haematol. 119:412–416. 2002. View Article : Google Scholar : PubMed/NCBI